Cerus (CERS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Timothy Lee - Head of Investor RelationsObi Greenman - President and CEOVivek Jayaraman - Chief Operating OfficerKevin Green - VP of Finance & CFOJosh Jennings - Managing DirectorCarol Moore - Senior Vice President of Regulatory Affairs, Quality & ClinicalMatthew Park - Equity Research AssociateVidyun Bais - Equity Research - Vice President Conference Call Participants None - Analyst Operator Good day, ladies and gentlemen. Tha ...

NV5 Global (NVEE) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Richard Tong - Director, EVP & General CounselDickerson Wright - Executive ChairmanBen Heraud - CEOEdward Codispoti - CFOAlexander Hockman - President & CEO - InfrastructureAndrew Chang - COO - Buildings & TechnologyKurt Allen - President of GeospatialSam Kusswurm - Equity Research Associate Conference Call Participants Chris Moore - Senior AnalystRob Brown - Founding Partner & Senior Research AnalystAndrew Wittmann - Seni ...

Financial Data and Key Metrics Changes - Ascendis Pharma reported a significant increase in first quarter revenue for Europath, reaching €44.7 million, up from €13.6 million in the previous quarter [28] - Total revenue for the first quarter was €101 million, which includes non-product revenue from collaboration partners [30] - R&D costs for the first quarter totaled €86.6 million, compared to €70.7 million in the same quarter of the previous year [30] - SG&A expenses increased to €101 million from €66.8 million year-over-year, primarily due to global commercial expansion [31] Business Line Data and Key Metrics Changes - Europath's global revenue grew to €45 million in the first quarter, reflecting strong U.S. demand and a growing patient base [13][28] - Skytrofa generated €51.3 million in revenue for the quarter, with stable pricing and market share despite seasonal impacts [29][19] - The company expects Europath to significantly contribute to revenue in 2025, with a potential to become a multi-billion euro product [18] Market Data and Key Metrics Changes - In the U.S., Europath was prescribed by over 1,000 unique prescribers for more than 1,750 patients, marking a successful launch [11] - The company estimates there are over 400,000 patients globally with chronic hypoparathyroidism, with 70,000 in the U.S. alone [18] - Skytrofa holds approximately 7% market share in the total growth hormone market in the U.S. and around 43% in the non-active growth hormone market [19] Company Strategy and Development Direction - Ascendis Pharma aims to be a leading biopharma company, focusing on the commercialization and development of Skytrofa and Europath [10] - The company is committed to expanding its product portfolio, with TransCon CNP being a key component in treating achondroplasia [12] - Ascendis Pharma is exploring market opportunities beyond endocrinology and rare diseases, indicating a strategic shift towards broader therapeutic areas [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong launch of Europath and its potential to become cash flow positive [10] - The company anticipates substantial revenue growth driven by the global launch of Europath and continued contributions from Skytrofa [32] - Management highlighted the importance of addressing unmet medical needs and the positive trends in reimbursement for Europath [38][40] Other Important Information - Ascendis Pharma's proprietary TransCon technology platform is fundamental to the development of its medicines, allowing for differentiated treatment benefits [26] - The company is collaborating with Novo Nordisk for the development of TransCon technology-based products in metabolic and cardiovascular diseases [27] Q&A Session Summary Question: What is the expected reimbursement rate for Yorvapath? - Management estimates that 17% to 18% of patients will ultimately get reimbursed once Yorvapath reaches steady state [38] Question: Can you provide the split between U.S. and ex-U.S. revenue for Yorvapath? - Management indicated that while specific numbers are not disclosed, there is steady growth expected outside the U.S. with an acceleration anticipated in the second half of the year [48] Question: What is the depth of prescribing for Yorvapath? - Management noted that they cannot definitively categorize patients as well-controlled or uncontrolled but expect a steady flow of patients transitioning from conventional therapies [66][70] Question: How is the company addressing payer dynamics? - Management emphasized that they are well-equipped to navigate reimbursement challenges, leveraging experience from previous product launches [75] Question: What are the competitive dynamics with new entrants in the market? - Management expressed confidence that their product addresses significant unmet medical needs and that new entrants may not significantly impact their market position [114]

AXT (AXTI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Leslie Green - Investor RelationsGary Fischer - CFO, VP & Corporate SecretaryMorris Young - Co-Founder, CEO & ChairmanRoss Cole - Equity Research AssociateTim Bettles - VP Business Development, Strategic Sales and MarketingMatthew Bryson - MD - Equity Research Conference Call Participants Richard Shannon - Senior Research AnalystDave Kang - Senior Analyst Operator Good afternoon, everyone, and welcome to AXT's First Quarter twent ...

Red Rock Resorts (RRR) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Stephen Cootey - Executive VP, CFO & TreasurerScott Kreeger - PresidentLorenzo Fertitta - Vice Chairman of the BoardJohn Decree - Director - Equity ResearchBarry Jonas - Managing DirectorDavid Katz - Managing DirectorSteven Wieczynski - Managing DirectorFrank Fertitta - Chairman & CEO Conference Call Participants Carlo Santarelli - AnalystShaun Kelley - Senior Research Analyst & MD - Gaming, Lodging & Leisure Equities ...

Traeger (COOK) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Nick Bacchus - VP of IR, Treasury & Capital marketsJeremy Andrus - CEODominic Blosil - Chief Financial OfficerSabrina Baxamusa - Equity Research Associate Conference Call Participants Anna Glaessgen - Senior Research AnalystPeter Benedict - Senior Research AnalystBrian McNamara - MD & Senior Analyst - ConsumerNone - Analyst Operator Good afternoon. Thank you for attending the Traeger First Quarter Fiscal twenty twenty five Ea ...

GeoVax Labs (GOVX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Dodd - Chairman, President & CEOMark Reynolds - CFOJames Molloy - Managing Director, Equity Research, Biotechnology & Specialty PharmaceuticalsJeffrey Kraws - Co-Founder & CEO Conference Call Participants Robert Leboyer - Senior Biotechnology Analyst Operator Good afternoon, and welcome everyone to the GeoVax First Quarter twenty twenty five Corporate Update Call. My name is Michelle, and I will facilitate today's c ...

OneSpan (OSPN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Joe Maxa - VP, IRVictor Limongelli - CEOJorge Martell - CFOTrevor Rambo - Software Equity Research Associate Conference Call Participants Catharine Trebnick - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystRudy Kessinger - Managing Director - Senior Equity Research Analyst Operator thank you for standing by. Welcome to the Q1 twenty twenty five OneSpan Earnings Conference Call. At this time, all partic ...

ICF International (ICFI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Lynn Morgen - PartnerJohn Wasson - Chairman, President & CEOBarry Broadus - Senior VP & CFOTim Mulrooney - Group Head–Global ServicesJoseph Vafi - Managing Director, Equity ResearchTobey Sommer - Managing DirectorKevin Steinke - Managing Director Conference Call Participants Marc Riddick - Business Services Analyst Operator Welcome to the First Quarter twenty twenty five ICF Earnings Conference Call. My name is Cori ...

Frontier Group Holdings (ULCC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Erdman - Senior Director-Investor RelationsBarry Biffle - CEO, President & DirectorJames Dempsey - PresidentRobert Schroeter - Sr VP, Chief Commercial OfficerMark Mitchell - Senior VP & CFOMichael Linenberg - Managing DirectorSavanthi Syth - MD - Airlines & Advance Air MobilityTom Fitzgerald - VP - Equity ResearchJames Baker - Managing Director & Investment SpecialistDuane Pfennigwerth - Senior Managing ...